Erick J. Lucera's Insider Trades & SAST Disclosures
Erick J. Lucera's most recent trade in Dyne Therapeutics Inc was a trade of 214,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 31, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Erick J. Lucera.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Dyne Therapeutics Inc | Erick J. Lucera | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 214,500 | 214,500 | - | - | Stock Option (Right to Buy) | |
| Dyne Therapeutics Inc | Erick J. Lucera | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 66,100 | 66,100 | - | 0 | Common Stock | |
| Beyond Air Inc | Erick J. Lucera | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Mar 2025 | 75,000 | 75,000 | - | - | Stock Options (Right to buy) | |
| Editas Medicine Inc | Erick J. Lucera | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2025 | 275,100 | 275,100 | - | - | Stock Option (right to buy) | |
| Editas Medicine Inc | Erick J. Lucera | EVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2025 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| Editas Medicine Inc | Erick J. Lucera | EVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 1.71 per share. | 04 Mar 2025 | 4,109 | 112,720 (0%) | 0% | 1.7 | 7,030 | Common Stock |
| Beyond Air Inc | Erick J. Lucera | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Nov 2024 | 45,000 | 0 | - | - | Stock Options (Right to buy) | |
| Beyond Air Inc | Erick J. Lucera | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Nov 2024 | 45,000 | 45,000 | - | - | Stock Options (Right to buy) | |
| Beyond Air Inc | Erick J. Lucera | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Nov 2024 | 40,000 | 40,000 | - | - | Stock Options (Right to buy) | |
| Beyond Air Inc | Erick J. Lucera | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Nov 2024 | 40,000 | 0 | - | - | Stock Options (Right to buy) | |
| Beyond Air Inc | Erick J. Lucera | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Nov 2024 | 30,000 | 0 | - | - | Stock Options (Right to buy) | |
| Beyond Air Inc | Erick J. Lucera | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Nov 2024 | 30,000 | 30,000 | - | - | Stock Options (Right to buy) | |
| Beyond Air Inc | Erick J. Lucera | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Nov 2024 | 25,000 | 0 | - | - | Stock Options (Right to buy) | |
| Beyond Air Inc | Erick J. Lucera | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Nov 2024 | 25,000 | 25,000 | - | - | Stock Options (Right to buy) | |
| Beyond Air Inc | Erick J. Lucera | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Nov 2024 | 25,000 | 0 | - | - | Stock Options (Right to buy) | |
| Beyond Air Inc | Erick J. Lucera | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Nov 2024 | 25,000 | 25,000 | - | - | Stock Options (Right to buy) | |
| Beyond Air Inc | Erick J. Lucera | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Nov 2024 | 25,000 | 0 | - | - | Stock Options (Right to buy) | |
| Beyond Air Inc | Erick J. Lucera | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Nov 2024 | 25,000 | 25,000 | - | - | Stock Options (Right to buy) | |
| Beyond Air Inc | Erick J. Lucera | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Nov 2024 | 20,000 | 0 | - | - | Stock Options (Right to buy) | |
| Beyond Air Inc | Erick J. Lucera | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Nov 2024 | 20,000 | 20,000 | - | - | Stock Options (Right to buy) | |
| Beyond Air Inc | Erick J. Lucera | Director | Purchase of securities on an exchange or from another person at price $ 0.40 per share. | 14 Aug 2024 | 39,266 | 43,608 (0%) | 0% | 0.4 | 15,565 | Common Stock |
| SAB Biotherapeutics Inc | Erick J. Lucera | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2024 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Editas Medicine Inc | Erick J. Lucera | EVP, CHIEF FINANCIAL OFFICER | 20 May 2024 | 22,337 | 116,829 (0%) | 0% | 5.6 | 125,404 | Common Stock | |
| Beyond Air Inc | Erick Lucera J. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2024 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Editas Medicine Inc | Erick J. Lucera | EVP, CHIEF FINANCIAL OFFICER | 02 Mar 2024 | 106,000 | 106,000 | - | - | Stock Option (right to buy) | ||
| Editas Medicine Inc | Erick J. Lucera | EVP, CHIEF FINANCIAL OFFICER | 02 Mar 2024 | 35,300 | 113,200 (0%) | 0% | 0 | Common Stock | ||
| Editas Medicine Inc | Erick J. Lucera | EVP, CHIEF FINANCIAL OFFICER | 02 Mar 2024 | 25,966 | 139,166 (0%) | 0% | 0 | Common Stock | ||
| Editas Medicine Inc | Erick J. Lucera | EVP, CHIEF FINANCIAL OFFICER | 17 May 2023 | 155,800 | 155,800 | - | - | Stock Option (right to buy) | ||
| Editas Medicine Inc | Erick J. Lucera | EVP, CHIEF FINANCIAL OFFICER | 17 May 2023 | 77,900 | 77,900 (0%) | 0% | 0 | Common Stock | ||
| SAB Biotherapeutics Inc | Erick J. Lucera | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 25,000 | 25,000 | - | - | Employee Stock Option (right to buy) | |
| Beyond Air Inc | Erick J. Lucera | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Beyond Air Inc | Erick J. Lucera | Director | Purchase of securities on an exchange or from another person at price $ 6.82 per share. | 16 Mar 2023 | 2,000 | 4,342 (0%) | 0% | 6.8 | 13,634 | Common Stock |
| Bone Biologics Corp | Erick J. Lucera | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2022 | 36,845 | 68,516 | - | - | Non-Employee Stock Option | |
| Beyond Air Inc | Erick J. Lucera | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Beyond Air Inc | Erick J. Lucera | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Beyond Air Inc | Erick J. Lucera | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.25 per share. | 16 Feb 2021 | 1,171 | 2,342 (0%) | 0% | 4.3 | 4,977 | Common Stock |
| Beyond Air Inc | Erick J. Lucera | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 1,171 | 0 | - | - | Tranche B Warrant (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges